Last reviewed · How we verify
DNA HIVIS and MVA-CMDR
DNA HIVIS and MVA-CMDR is a Biologic drug developed by Instituto Nacional de Saúde, Mozambique. It is currently in Phase 1 development.
At a glance
| Generic name | DNA HIVIS and MVA-CMDR |
|---|---|
| Sponsor | Instituto Nacional de Saúde, Mozambique |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DNA HIVIS and MVA-CMDR CI brief — competitive landscape report
- DNA HIVIS and MVA-CMDR updates RSS · CI watch RSS
- Instituto Nacional de Saúde, Mozambique portfolio CI
Frequently asked questions about DNA HIVIS and MVA-CMDR
What is DNA HIVIS and MVA-CMDR?
DNA HIVIS and MVA-CMDR is a Biologic drug developed by Instituto Nacional de Saúde, Mozambique.
Who makes DNA HIVIS and MVA-CMDR?
DNA HIVIS and MVA-CMDR is developed by Instituto Nacional de Saúde, Mozambique (see full Instituto Nacional de Saúde, Mozambique pipeline at /company/instituto-nacional-de-sa-de-mozambique).
What development phase is DNA HIVIS and MVA-CMDR in?
DNA HIVIS and MVA-CMDR is in Phase 1.